The aim of this study was to present the midterm results of total hip arthroplasty with ultra-short anatomical cementless stem in the primary treatment of displaced intracapsular femoral neck fractures in patients younger 60 years. From 2006 to 2015, 17 hip arthroplasties (with the Proxima stem) were performed in group of 17 patients for the treatment of acute femoral neck fractures Garden type III and IV. The mean follow-up period was 112.7 (range: 64-148) months. Patients were evaluated retrospectively - clinically and radiographically, using the Harris hip scoring system during the year 2020. Seven males and ten females (mean age: 45.0 years) were included in the study. Each of them had one or more risk factors (time delay, comminution of the femoral neck, corticosteroids usage, the presence of coxarthrosis, rheumatoid arthritis, alcohol abuse, etc…), because of which the osteosynthesis was not performed. Harris hip scores were 6.3 preoperatively and 82.9 at the final follow-up. Three patients (17.6%) had complications: luxation, aseptic stem loosening (migration with subsidence - "varisation" and thigh pain) and deep infection. One patient (5.9%) with infection was revised. In carefully selected younger patients with displaced intracapsular femoral neck fracture, where the osteosynthesis as first treatment option should be associated with high risk of complication (avascular femoral head necrosis, non-union) due to the presence of risk factors, the primary total hip arthroplasty could be performed. The ultra-short cementless stem offers promising results in these rare cases in the midterm.

Download full-text PDF

Source
http://dx.doi.org/10.52628/87.4.06DOI Listing

Publication Analysis

Top Keywords

femoral neck
20
intracapsular femoral
12
neck fractures
12
ultra-short cementless
8
fractures patients
8
patients younger
8
younger years
8
total hip
8
hip arthroplasty
8
cementless stem
8

Similar Publications

Purpose: To investigate the relationship between serum uric acid (SUA) levels and femoral neck bone mineral density (BMD) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD).

Patients And Methods: This cross-sectional study included 597 adult inpatients with type 2 diabetes mellitus and ultrasonography-confirmed fatty liver disease. Participants were stratified into tertiles based on femoral neck BMD.

View Article and Find Full Text PDF

Objectives: Treating femoral neck fractures remains a significant challenge for orthopedic surgeons and imposes a substantial economic burden on developing regions. Current novel internal fixation methods demonstrate excellent biomechanical performance. However, these new internal fixation methods are still associated with various complications.

View Article and Find Full Text PDF

The essential cause of menopause is ovarian failure, which can cause decline in sex hormones (especially estrogen) that can increase the risk of metabolic diseases, such as cardiovascular disease and osteoporosis. This study screened 1511 eligible patients from 2148 perimenopausal and postmenopausal women, measuring various physiological and biochemical indicators to analyze differences among age groups (40-44, 45-49, and 50-54 years) with laboratory techniques. The study found no significant difference in the incidence of cardiovascular disease betweenperimenopausal and postmenopausal women.

View Article and Find Full Text PDF

Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus.

Lupus Sci Med

January 2025

Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Objective: Osteoporosis is a common comorbidity in patients with SLE, and bone loss in patients with SLE has a multifactorial aetiology. This study aimed to evaluate the therapeutic efficacy of denosumab in patients with SLE with osteoporosis and to analyse the factors influencing therapeutic efficacy.

Methods: A total of 166 patients with SLE with osteoporosis who initiated denosumab between January 2016 and December 2023 were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!